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Abstract
Thirteen new N-aryl 1,2,3,4-tetrahydroquinoline compounds (4a–f, 6a–c, and 8a–d) were 
synthesized and evaluated for antitumor activity and drug-like properties. Compound 4a exhibited 
high inhibitory potency with low nanomolar GI50 values of 16–20 nM in cellular assays, including 
excellent activity against the P-glycoprotein overexpressing cell line KBvin. Compound 4a 
inhibited colchicine binding to tubulin and tubulin assembly with an IC50 value of 0.85 μM, 
superior to the reference compound CA4 (1.2 μM) in the same assay. In addition, 4a also exhibited 
highly improved water solubility (75 μg/mL) and a suitable log P value (3.43) at pH 7.4. With a 
good balance between antitumor potency and drug-like properties, compound 4a could be a new 
potential drug candidate for further development. Current results on SAR studies and molecular 
modeling provided more insight about this class of compounds as tubulin polymerization 
inhibitors targeting the colchicine site.
Graphical Abstract
*Corresponding authors: Tel/fax: +86 10 66931690 (L. Xie); Tel: +1 919 962 0066, fax: +1 919 966, 3893 (K.-H. Lee); 
lanxieshi@yahoo.com (L. Xie); khlee@unc.edu (K.-H. Lee).
||The authors contributed equally to this work
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Bioorg Med Chem. Author manuscript; available in PMC 2016 September 01.
Published in final edited form as:














N-Aryl 1,2,3,4-tetrahydroquinolines; Cytotoxic activity; Tubulin polymerization inhibitors; 
Colchicine binding inhibitors
1. Introduction
Microtubules play critical roles in cell division. They form the mitotic spindle, which directs 
and monitors the movement and attachment of chromosomes during mitosis and, thus, 
microtubules provide a target for anticancer drug development. The antitumor drugs 
paclitaxel and vinblastine, as well as related analogs, interfere with microtubule dynamics,1 
either stabilizing microtubules or inhibiting tubulin polymerization, respectively, and are 
widely used as first-line drugs in clinical treatments. However, high toxicity and the 
development of drug resistance greatly limit their effectiveness. Recently, diverse small 
molecules binding at the colchicine site (CS) of tubulin2,3,4 have undergone extensive 
development as vascular-disrupting agents (VDAs).5 VDAs with high cytotoxicity for 
human tumor cells target the vasculature induced by solid tumors, shut down blood flow to 
tumor cells, and cause cancer cell death via extensive necrosis and apoptosis, while blood 
flow in normal tissues remains relatively intact.6 A dozen VDA drug candidates targeted at 
the CS are currently in clinical development as cancer treatments,7,8 e.g., combretastatin A-4 
(CA-4), its phosphate derivative CA-4P,9 BNC105,10 and verubulin (MPC-6827),11 as 
shown in Figure 1, but none has an approved New Drug Application. Thus, continuous 
development of CS agents with novel structures or unique binding to the CS is needed to 
determine the optimal drug candidate.
In our prior studies on anticancer agents,12,13,14 we discovered new N-aryl 6-
methoxy-1,2,3,4- tetrahydroquinolines as potent tubulin polymerization inhibitors targeting 
the CS. We found high cytotoxicity in cellular assays and inhibitory potency in tubulin 
assembly and colchicine binding assays, resulting in two leads, N-(2′-substituted-
quinazol-4′-yl)-6-methoxy-1,2,3,4- tetrahydroquinolines 1a and 1b (Figure 2). 
Subsequently, we performed structural optimizations on 1a, modifying either the piperidine 
ring (B-ring) or the quinozoline ring (A-ring), to elucidate structure-activity relationship 
(SAR) and structure-property relationship (SPR) correlations aimed at developing potential 
new drug candidates. The B-ring modification studies revealed some correlative SARs and 
resulted in promising potential drug candidates with a new scaffold and high antitumor 
potency in vitro and in vivo.15 Meanwhile, modifications on the quinazoline ring (A-ring) of 
1a were also carried out in parallel, and related results are reported herein. Our continued 
optimization focused first on the 2-Cl group in 1a becuase of its chemical reactivity, which 
could lead to lower metabolic stability (1a, t1/2 10.6 min) and present potential liability for 
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further development. Because the previously synthesized 2-methylamino lead 1b exhibited 
improved aqueous solubility and metabolic stability compared with 1a (Figure 2),11 we 
postulated that the 2-substituent on the quinazoline ring (A ring) might improve drug-like 
properties without loss of antitumor potency. Therefore, we introduced several substituted 
amino or alkoxy groups at the 2-position on the quinazoline, resulting in new compounds 
4a–f. Next, we replaced the quinazoline, a common moiety in many kinase inhibitors as well 
as the known VDA candidate MPC-6827, in 1a (Figure 1), with other bioisomeric hetero-
aromatic cyclic rings, such as unsubstituted and substituted purines (6 series), quinoline, and 
isoquinoline (8 series) (Figure 2), to explore new antitumor agents with different scaffold(s). 
Complementary to our prior structural optimizations,12 our current results with three new 
series 4, 6, and 8 are reported herein, including chemical synthesis, antitumor activity in 
vitro, drug-like property evaluation, molecular modeling, and SAR analysis.
2. Chemistry
The designed new N1-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines 4a–f and 6a–c were 
synthesized as shown in Schemes 1 and 2. According to previous methods,11 lead 1a was 
prepared by coupling 6-methoxy-1,2,3,4-tetrahydroquinoline (3)16 and 2,4-
dichloroquinazoline (2a) in the presence of NaHCO3 in anhydrous EtOH at reflux. 
Subsequently, the 2-chloro in 1a was converted to a substituted amino group by nucleophile 
reaction with 3-aminopropanol, cyclopropylamine, or cyclopenylamine in ethanol under 
microwave (mw) irradiation at 150 ºC for 15 min to afford corresponding compounds 4a–c, 
respectively, in yields ranging from 71 to 96%. Under the same reaction conditions, 
compound 4d with a 2-dimethylamino group was obtained from 1a and DMF, serving as 
both dimethylamine source17 and solvent. Reaction of 1a with NaOMe in methanol at reflux 
produced 2-methoxyquinazoline compound 4e in 88% yield. While 1a was obtained under 
alkaline conditions, compound 3 was coupled with commercially available 4-
chloroquinazoline (2b) in the presence of HCl in i-PrOH at reflux to afford N-(4-
quinazolyl)-6-methoxy-1,2,3,4- tetrahydroquinoline 4f. Similarly, N1-(6-purinyl)-6-
methoxy-1,2,3,4-tetrahydroquinolines 6a–c were synthesized from 3 and a 6-chloro-9H-
purine (5a, b or c) (Scheme 2). Finally, compound 3 was coupled with a halo-quinoline or -
isoquinoline (7a–d) in the presence of Pd(OAc)2, X-phos (ratio 2%–4%), and Cs2CO3 in 
toluene at reflux to provide corresponding N1-aryl substituted 6-methoxy-1,2,3,4-
tetrahydroquinolines 8a–d, respectively. All new target compounds 4, 6, and 8 were 
identified from 1H NMR and MS spectroscopic data, and their purities were greater than 
95% as measured by HPLC.
3. Results and discussion
3.1. Evaluation of cytotoxicity and tubulin inhibition activity in vitro
The newly synthesized N-aryl substituted 6-methoxy-1,2,3,4-tetrahydroquinolines, series 4, 
6 and 8, were first tested in cellular assays to evaluate in vitro antitumor activity. A panel of 
human tumor cell lines (HTCL) including A549 (lung carcinoma), KB (epidermoid 
carcinoma of the mouth), KBvin, a P-glycoprotein overexpressing multidrug-resistant cell 
line (vincristine-resistant KB),18,19 and DU145 (prostate cancer) was used with paclitaxel as 
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a reference. The potency (GI50) in vitro was determined using the established 
sulforhodamine B (SRB) method,20 and data are shown in Tables 1 and 2.
All six series 4 compounds with a 2-substituted quinazoline B-ring system exhibited 
significant cytotoxicity against the growth of the tested HTCL (Table 1). Among them, 
compounds 4a, b, e, and f showed low nanomolar GI50 values ranging from 13 to 30 nM, 
comparable to lead 1b but less potent than 1a (1.5–1.7 nM). With low to sub-micromolar 
GI50 values (0.14–1.42 μM), the 2-cyclopentylamino- (4c) and 2-N,N-dimethylamino (4d) 
compounds were at least 10 times less potent than 4a,b,e,f, indicating that more bulk at the 
2-position on the quinazoline was not favorable for cytotoxic activity. Furthermore, potency 
dropped dramatically when the quinazoline moiety was replaced by a purine without or with 
a substituent (6a–c, GI50 > 17.53 μM) (Table 1). However, compounds 8a–c with a 
quinoline or isoquinoline rather than quinazoline showed moderate cytotoxicity with GI50 
values of 0.16–2.08 μM, while 8d was less potent (GI50 8.71–16.2 μM) in the cellular assay 
(Table 2). These results indicated that the quinazoline ring could be changed, but more 
investigations are warranted.
The data in Tables 1 and 2 also demonstrate that all newly synthesized compounds, unlike 
paclitaxel, have equivalent activities in the KB and KBvin cell lines. The latter 
overexpresses the drug transporter P-glycoprotein, resulting in a multidrug resistant 
phenotype.
Next, selected compounds from the cellular cytotoxicity assays were evaluated in tubulin 
assembly inhibition and colchicine binding assays for comparison with the control CA-4, a 
phase III clinical candidate. These data are shown in Table 3. As expected, the most 
cytotoxic compounds 4a, 4b, and 4f also exhibited high potency in the tubulin assembly 
assay with low micromolar (1.3 μM, 4b and 4f) or sub-micromolar (0.85 μM, 4a) IC50 
values, comparable with or better than the value obtained with CA4 (IC50 1.2 μM). The 
three compounds also inhibited colchicine binding to tubulin. In addition, the moderately 
potent compounds 4c, 8a, and 8b (GI50 values, 0.92–2.08 μM) and less active compound 8d 
(GI50 8.71–16.2 μM) from the cellular cytotoxicity assay were also tested against tubulin 
assembly and colchicine binding in cell-free assays. Compared with 4a, 4b, and 4f, 
compounds 4c, 8a, 8b showed lower potency, with assembly IC50 values ranging from 2.6 
to 5.7 μM and less than 40% inhibition of colchicine binding at 5 μM, whereas 8d did not 
display significant inhibitory activity in the assembly assay. The consistency of the results 
between the cellular and cell-free assays, as well as with our previous results, confirms that 
our new active compounds are tubulin polymerization inhibitors targeting the CS.
Next, selected compounds from the cellular cytotoxicity assays were evaluated in tubulin 
assembly inhibition and colchicine binding assays for comparison with the control CA-4, a 
phase III clinical candidate. These data are shown in Table 3. As expected, the most 
cytotoxic compounds 4a, 4b, and 4f also exhibited high potency in the tubulin assembly 
assay with low micromolar (1.3 μM, 4b and 4f) or sub-micromolar (0.85 μM, 4a) IC50 
values, comparable with or better than the value obtained with CA4 (IC50 1.2 μM). The 
three compounds also inhibited colchicine binding to tubulin. In addition, the moderately 
potent compounds 4c, 8a, and 8b (GI50 values, 0.92–2.08 μM) and less active compound 8d 
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(GI50 8.71–16.2 μM) from the cellular cytotoxicity assay were also tested against tubulin 
assembly and colchicine binding in cell-free assays. Compared with 4a, 4b, and 4f, 
compounds 4c, 8a, 8b showed lower potency, with assembly IC50 values ranging from 2.6 
to 5.7 μM and less than 40% inhibition of colchicine binding at 5 μM, whereas 8d did not 
display significant inhibitory activity in the assembly assay. The consistency of the results 
between the cellular and cell-free assays, as well as with our previous results, confirms that 
our new active compounds are tubulin polymerization inhibitors targeting the CS.
3.2. Physicochemical property evaluations
Representative active compounds 4a and 4b were further evaluated for aqueous solubility, 
which is good drug-like property, especially for antitumor drugs given via intravenous 
administration, and logP parameters at pH 7.4 by using HPLC methodology.21 As expected, 
compared with 1a (0.45 μg/mL), compound 4a, with a polar 2-hydroxypropylamino group 
on the quinazoline, showed greatly improved aqueous solubility (75.6 μg/mL), while 
compound 4b with the more lipophilic 2-cyclopropylamino group displayed less improved 
aqueous solubility (2.55 μg/mL) (Table 4). Consistent with the solubility results, 4a had a 
more suitable log P value (3.45) than 4b (log P 4.13). Therefore, compound 4a could be a 
potential anticancer drug candidate for further development by evaluating its in vivo 
activity.
3.3. Molecular modeling
In an attempt to better understand the molecular basis of 4a as a tubulin inhibitor, we 
modeled compound 4a into the CS in the tubulin dimer by using the CDOCKER program in 
the Discovery Studio 3.0 software with the tubulin crystal structure (PDB: 1SA0).22 As 
shown in Figure 3, the binding conformation of 4a (orange) displayed a lower energy 
(−46.11 kcal/mol) than lead 1a (−38.68 kcal/mol) and superimposed well with 1a (pink) and 
original ligand DAMA-colchicine (cyan) in the tubulin crystal structure. From literature 
reports,23,24 Cys241 in β-H7 of tubulin is a key amino acid that anchors most inhibitors, and 
its side chain forms a hydrogen bond with the oxygen atom of the 2-OCH3 on the phenyl 
ring (C-ring) of DAMA-colchicine. Like lead 1a, compound 4a also formed a hydrogen 
bond from the 6-OCH3 group on the tetrahydroquinoline ring (B/C-ring) with Cys241. The 
tetrahydroquinoline ring in 4a and 1a overlapped well with the trimethoxyphenyl portion of 
DAMA-colchicine. Meanwhile, the cyclic linker in 4a extended toward a lipophilic cavity 
surrounded with lipophilic amino acid residues, Leuβ242, Alaβ250, Leuβ252 and Leuβ255, 
but only Leuβ255 was close enough to the cyclic linker to be within distance of van der 
Waal’s force. Thus, we suggest that the cyclic linker could be further modified to have more 
interactions with the lipophilic cavity to enhance the affinity of this compound type with the 
colchicine binding site of tubulin. Compared with 1a, the terminal hydroxy group of the 2-
substituent on the quinazoline ring of 4a formed an additional hydrogen bond with Ser178 in 
the α-T5 loop of tubulin. Although these hydrogen bonds between tubulin and the thiol 
group of DAMA-colchicine were observed, intact colchicine may not form these hydrogen 
bonds. Additionally, we observed that the linear 2-hydroxypropylamino group in 4a was 
oriented similarly to the mercaptoacetamido (−HNCOCH2SH) group in DAMA-colchicine, 
and both superimposed well. Thus, the flexible 2-hydroxypropylamino group could attain a 
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suitable conformation to interact with amino acids of the tubulin binding site to enhance 
molecular affinity.
4. Conclusion
By modifying the quinazoline ring moiety of lead 1a, we synthesized 13 new 1,2,3,4-
tetrahydroquinoline compounds, 4a–f, 6a–c, and 8a–d, with various N-aryl substituents. 
Compound 4a showed high inhibitory potency in the tubulin polymerization assay (IC50 
0.85 μM), targeting the CS, with greater potency than the reference compound CA-4 (1.2 
μM). Compound 4a also strongly inhibited the growth of human tumor cells with low 
nanomolar GI50 values (16–20 nM). Compound 4a was fully active in a multidrug resistant 
cell line overexpressing P-glycoprotein. Notably, active compound 4a also exhibited highly 
improved water solubility (75 μg/mL) and a suitable log P value (3.43) at pH 7.4 that are 
better than those of lead 1a and other new compounds. Thus, compound 4a could be a 
potential drug candidate for further development. Meanwhile, the current results also 
revealed additional SAR information. (1) The 2-substituent on the quinazoline ring is 
modifiable to enhance or maintain molecular antitumor activity (4a–b, 4e–f), but a bulky 
group is unfavorable (4c and 4d). (2) The quinazoline ring is a better moiety than purine (cf. 
6 series, which exhibited much lower activity) for antitumor activity but is replaceable (cf. 8 
series with quinoline or isoquinoline ring, which maintained low micromolar GI50 values). 
(3) The polar hydroxypropylamino substituent is favorable due to its flexibility and H-bond 
forming ability, resulting in a good balance between potency and drug-like properties. 
Molecular modeling results provided additional insight on the interactions of 4a with the 
tubulin colchicine site. These current results complement our prior studies and will help us 
to further optimize and develop new drug candidates for clinical studies as novel tubulin 
inhibitors targeting the CS.
5. Experimental section
5.1. Chemistry
All commercial chemical reagents were purchased from Beijing Chemical Works or Sigma-
Aldrich, Inc. Proton nuclear magnetic resonance (1H NMR) spectra were measured on a 
JNM-ECA-400 (400MHz) spectrometer using tetramethylsilane (TMS) as internal standard. 
The solvent used was CDCl3 unless otherwise indicated. Mass spectra (MS) were measured 
on an API-150 mass spectrometer with an electrospray ionizer from ABI, Inc., and data are 
presented as intensity of ion peak (%). Melting points were measured by a SGW X-4 Micro-
Melting point detector without correction. Microwave-assisted reactions were performed on 
a reactor from Biotage, Inc. Medium-pressure column chromatography was performed using 
a CombiFlash Companion system from ISCO, Inc. Thin-layer chromatography (TLC) was 
performed on silica gel GF254 plates. Aqueous solubility and log P of target compounds 
were determined by using an Agilent 1200 HPLC system with UV detector and an Agilent 
Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm), flow rate 0.8 mL/min, UV detection at 
254 nm, and injection volume of 20 μL. The mobile elution is a mixture of solvents MeOH 
and water (80:20) contained 0.04% ammonium acetate. The purity of target compounds was 
also measured by HPLC using the above conditions, unless otherwise indicated. The 
preparation of 1a was reported in our previous publication.11
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tetrahydro- quinoline (4a)—A mixture of 1a (145 mg, 0.44 mmol) and 3-aminopropanol 
(0.1 mL, excess) in EtOH (2.5 mL) was stirred under mw irradiation at 150 ºC for 15 min. 
The mixture was poured into ice-water, extracted with EtOAc, and washed with water to 
neutral. After removal of solvent, crude product was purified on a silica column with 
gradient elution (MeOH/CH2Cl2 0–5%) by a CombiFlash system to produce 137 mg of 4a 
in 71% yield, yellow solid, mp 134~136 ºC; 1H NMR δppm 1.77 (2H, t, J = 7.2 Hz, CH2), 
2.07 (2H, m, 3-CH2), 2.85 (2H, t, J = 6.8 Hz, PhCH2), 3.67(4H, m, 2×CH2), 3.79 (3H, s, 
OCH3), 3.93(2H, t, J = 6.8 Hz, 2-NCH2), 6.56 (1H, dd, J = 8.8 and 2.8 Hz, PhH-7), 6.70 
(1H, d, J = 8.8 Hz, PhH-8), 6.77 (1H, d, J = 2.8Hz, PhH-5), 6.84 (1H, m, ArH-6), 7.25 (1H, 
d, J = 8.0 Hz, ArH-5), 7.47 (2H, m, ArH-7,8), MS m/z (%) 365 (M + H)+; 13C NMR δppm 
24.10, 27.11, 33.90, 37.01, 47.38, 55.39, 57.76, 111.86, 113.34, 120.76, 122.95, 124.99, 
126.54, 132.16,, 132.79 (C×2), 135.67, 152.78, 155.87, 159.78, and 163.02; HPLC purity 
98.9%.
5.1.2. N1-(2′-Cyclopropylaminoquinazol-4′-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (4b)—Prepared in the same manner as 4a. Starting with 1a (50 mg, 
0.15 mmol) and cyclopropanamine (0.1 mL, excess) in EtOH (2.5 mL) under mw irradiation 
at 150 ºC for 15 min to provide 51 mg of 4b in 97% yield, yellow solid, mp 173~175 ºC; 1H 
NMR (DMSO-d6) δ ppm 0.51 (2H, m, CH2), 0.66 (2H, m, CH2), 1.97 (2H, m, 3-CH2), 2.81 
(3H, m, PhCH2 and CH), 3.71 (3H, s, OCH3), 3.82 (2H, t, J = 6.4 Hz, 2-CH2N), 6.56 (1H, 
dd, J = 8.8 and 2.4 Hz, PhH-7), 6.68 (1H, d, J = 8.8 Hz, PhH-8), 6.76 (1H, d, J = 2.4 Hz, 
PhH-5), 6.84 (1H, m, ArH-6), 7.29 (1H, d, J = 8.8 Hz, ArH-5), 7.45 (1H, m, ArH-7),
7.54(1H, d, J = 8.8 Hz, ArH-8); MS m/z (%) 347 (M + H)+; HPLC purity 95.2%.
5.1.3. N1-(2′-Cyclopentyl)aminoquinazol-4′-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (4c)—Prepared in the same manner as 4a. Starting with 1a (150 mg, 
0.45 mmol) and cyclopentanamine (0.1 mL, excess) in EtOH (2.5 mL) under mw irradiation 
at 150 ºC for 15 min to afford 138 mg of 4c in 80% yield, yellow solid, mp 178~180 ºC; 1H 
NMR (DMSO-d6) δ ppm 1.54 (4H, m, 2×CH2), 1.68 (2H, m, CH2), 1.92 (2H, m, CH2), 1.98 
(2H, m, 3-CH2), 2.81 (2H, t, J = 6.8 Hz, PhCH2), 3.71 (3H, s, OCH3), 3.82 (2H, t, J = 6.8 
Hz, NCH2), 4.28 (1H, m, CH), 6.55 (1H, dd, J = 8.8 and 2.4 Hz, PhH-7), 6.68 (1H, d, J = 
8.8 Hz, PhH-8), 6.78 (1H, d, J = 2.4 Hz, PhH-5), 6.88 (1H, m, ArH-6), 7.24 (1H, d, J = 8.8 
Hz, ArH-5), 7.45 (1H, m, ArH-7), 7.54 (1H, d, J = 8.8 Hz, ArH-8); 13C NMR δppm 23.88 
(C×2), 24.28, 27.38, 33.68 (C×2), 47.39, 53.01, 55.53, 111.86, 113.44, 120.21, 122.67, 
125.84, 126.58, 131.86,, 132.44 (C×2), 136.38, 154.37, 155.57, 159.25, and 163.14; MS m/z 
(%) 375 (M + H)+; HPLC purity 99.2% (elution CH3CN/water 70:30).
5.1.4. N1-(2′-Dimethylaminoquinazol-4′-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (4d)—A solution of 1a (50 mg, 0.15 mmol) in DMF (2 mL) in the 
presence of 0.1 mL of ammonium hydroxide (NH3·H2O) was heated with stirring under mw 
irradiation at 150 ºC for 15 min. The mixture was poured into ice-water, and a yellow solid 
was filtered and washed with water until neutral. The crude product was purified by a flash 
chromatography (gradiant elution: MeOH/ CH2Cl2 0–5%) to provide 45 mg of 4d in 88% 
yield, light yellow solid, mp 89~91 ºC; 1H NMR δ ppm 2.08 (2H, m, 3-CH2), 2.85 (2H, t, J 
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= 6.8 Hz, PhCH2), 3.27 (6H, s, 2×NCH3), 3.78 (3H, s, OCH3), 3.97 (2H, t, J = 6.8 Hz, 
NCH2), 6.53 (1H, dd, J = 8.8 and 2.8 Hz, PhH-7), 6.65 (1H, d, J = 8.8 Hz, PhH-8), 6.77 (2H, 
m, PhH-5 and ArH-6), 7.23 (1H, d, J = 8.0 Hz, ArH-5), 7.42 (1H, m, ArH-7), 7.50 (1H, d, J 
= 8.0 Hz, ArH-8); MS m/z (%) 335 (M + H)+; HPLC purity 97.5%.
5.1.5. N1-(2′-Methoxyquinazol-4′-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline 
(4e)—A mixture of 1a (81 mg, 0.25 mmol) in anhydrous MeOH (4 mL) and NaOMe (34 
mg, 0.62 mmol) was refluxed for 1 h. The mixture was poured into ice-water with stirring 
and neutralized with HCl (2 N). The solid product was collected on a filter, washed with 
water until neutral, and dried to obtain 71 mg of pure 4e, 88% yield, pale yellow solid, mp 
161–163 ºC; 1H NMR δ ppm 2.09 (2H, m, 3-CH2), 2.85 (2H, t, J = 6.8 Hz, PhCH2), 3.80 
(3H, s, OCH3), 4.03 (2H, t, J = 6.8 Hz, NCH2), ), 4.09 (3H, s, OCH3), 6.53 (1H, dd, J = 8.8 
and 2.8 Hz, PhH-7), 6.67 (1H, d, J = 8.8 Hz, PhH-8), 6.79 (1H, J = 2.8 Hz, PhH-5), 6.98 
(1H, m, ArH-6), 7.23 (1H, d, J = 8.4 Hz, ArH-5), 7.56 (1H, m, ArH-7), 7.68 (1H, d, J = 8.4 
Hz, ArH-8); MS m/z (%) 322 (M + H)+; HPLC purity 98.8%.
5.1.6. 6-Methoxy-N1-(4′-quinazolyl)-1,2,3,4-tetrahydroquinoline (4f)—A mixture 
of 4-chloroquinazoline (2b, 170 mg, 1.04 mmol) and 6-methoxy-1,2,3,4-tetrahydroquinoline 
(3, 180 mg, 1.10 mmol) in i-PrOH (15 mL) with a drop of HCl (conc.) was refluxed for 1 h 
monitored by TLC until the reaction was completed. The mixture was poured into ice-water, 
adjusted to neutral pH with NaHCO3, extracted with EtOAc three times, and dried over 
anhydrous Na2SO4. After removal of solvent, the product was purified on a silica 
chromatographic column with gradient elution (MeOH/CH2Cl2 0–5%) to furnish 193 mg of 
4f in 65% yield, light yellow solid, mp 94~95 ºC; 1H NMR δ ppm 2.11 (2H, t, J = 6.8 Hz, 3-
CH2), 2.87 (2H, t, J = 6.8 Hz, 4-CH2), 3.80 (3H, s, OCH3), 4.05 (2H, t, J = 6.8 Hz, 2-CH2), 
6.56 (1H, dd, J = 8.8 and 2.8 Hz, PhH-7), 6.65 (1H, d, J = 8.8Hz, PhH-8), 6.79 (1H, d, J = 
2.8 Hz, PhH-5), 7.21 (1H, t, J = 8.8 Hz, ArH-6), 7.49 (1H, d, J = 8.8 Hz, ArH-5), 7.68 (1H, 
t, J = 8.8 Hz, ArH-7), 7.89 (1H, d, J = 8.8 Hz, ArH-8), 8.86 (1H, s, ArH-2); MS m/z (%) 
292.2 (M + H)+; HPLC purity 98.4%.
5.1.7. N1-(6-Purin-9H-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline (6a)—A mixture 
of 3 (180 mg, 1.10 mmol) and 6-chloro-9H-purine (5a, 150 mg, 0.97 mmol) in i-propanol 
(15 mL) in the presence of 1 drop of HCl (conc.) was refluxed for 5 h. When the reaction 
was complete, the mixture was poured into ice-water, adjusted to neutral pH, extracted with 
EtOAc, and dried over anhydrous Na2SO4. After removal of solvent in vacuo, crude product 
was purified by flash silica column chromatography (gradient elution: MeOH/CH2Cl2, 0–
5%) to produce 201 mg of 6a in 74% yield, white solid, mp 189~191 ºC; 1H NMR δ ppm 
2.10 (2H, m, 3-CH2), 2.87 (2H, t, J = 6.4 Hz, PhCH2), 3.82 (3H, s, OCH3), 4.59 (2H, t, J = 
6.4 Hz, NCH2), 6.73 (1H, s, PhH-5), 6.77 (1H, dd, J = 8.8 and 2.4 Hz, PhH-7), 7.52 (1H, d, 
J = 8.8 Hz, PhH-8), M8.03 (1H, s, ArH-8), 8.48 (1H, s, ArH-2); MS m/z (%) 282 (M + H)+; 
HPLC purity 97.2%.
5.1.8. N1-(2-Fluoro-9H-purin-6-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline (6b)—
Prepared in the same manner as 6a. Starting with 6-chloro-2-fluoro-9H-purine (5b, 110 mg, 
0.64 mmol) and 3 (115 mg, 0.70 mmol) in i-propanol at reflux for 4 h to furnish 137 mg of 
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6b in 73% yield, white solid, mp 218–220 ºC; 1H NMR δ ppm 2.12 (2H, m, 3-CH2), 2.86 
(2H, t, J = 6.8 Hz, PhCH2), 3.82 (3H, s, OCH3), 4.59 (2H, t, J = 6.8 Hz, NCH2), 6.71 (1H, d, 
J = 2.8 Hz, PhH-5), 6.77 (1H, dd, J = 8.8 and 2.8 Hz, PhH-7), 7.54 (1H, d, J = 8.8 Hz, 
PhH-8), 7.93 (1H, s, ArH-8); MS m/z (%) 300 (M + H)+.
5.1.9. N1-(2-Aminopurin-9H-6-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline (6c)—
Prepared in the same manner as 6a. Starting with 2-amino-6-chloro-9H-purine (5c, 150 mg, 
0.89 mmol) and 3 (160 mg, 0.98 mmol) in i-propanol for 4.5 h to obtain 157 mg of 6c in 
61% yield, white solid, mp 183~186 ºC; 1H NMR (DMSO-d6) δppm 1.85 (2H, m, 3-CH2), 
2.73 (2H, t, J = 6.0 Hz, PhCH2), 3.69 (3H, s, OCH3), 4.33 (2H, t, J = 6.0 Hz, NCH2), 5.72 
(2H, bs, NH2), 6.66 (2H, m, PhH), 7.32 (1H, J = 8.8 Hz, PhH), 7.70 (1H, s, ArH), 12.22 
(1H, s, NH). MS m/z (%) 297 (M + H)+; HPLC purity 94.5% (elution CH3CN/water 70:30).
5.1.10. N1-(1-Isoquinolin-1-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline (8a)—A 
mixture of 1-bromoisoquinoline (7a, 170 mg, 0.83 mmol) and 3 (150 mg, 0.92 mmol) in the 
presence of Cs2CO3 (2 equiv.), X-Phos (5% equiv), and Pd(OAc)2 (4% equiv) in toluene (15 
mL) was refluxed for 26 h. The mixture was added to EtOAc, unsoluble solid filtered out, 
and solvent removed under reduced pressure. The crude product was purified on a silica 
column with gradiant elution (EtOAc/petroleum ether, 0–30%) to provide 180 mg of 8a in 
75% yield, yellow solid, mp 121~122 ºC; 1H NMR δ ppm 2.12 (2H, t, J = 6.0 Hz, 3-CH2), 
2.95 (2H, t, J = 6.0 Hz, PhCH2), 3.74 (3H, s, OCH3), 3.86 (2H, t, J = 6.0 Hz, NCH2), 6.33 
(1H, d, J = 8.8 Hz, PhH-8), 6.45 (1H, dd, J = 8.8 an 2.0 Hz, PhH-7), 6.70 (1H, d, J = 2.0 Hz, 
PhH-5), 6.99 (1H, d, J = 8.0 Hz, ArH-4), 7.40 (1H, t, J = 8.0 Hz, ArH-7), 7.61 (1H, t, J = 8.0 
Hz, ArH-6), 7.78 (1H, d, J = 8.0 Hz, ArH-5), 7.93 (1H, d, J = 8.0 Hz, ArH-8), 8.28 (1H, s, 
ArH-3); MS m/z (%) 291 (M + H)+; HPLC purity 96.0%.
5.1.11. N1-(4-Isoquinolinyl)-6-methoxy-1,2,3,4-tetrahydroquinoline (8b)—
Prepared in the same manner as 8a. Starting with 4-bromoisoquinoline (7b, 170 mg, 0.83 
mmol) and 3 (150 mg, 0.92 mmol), Cs2CO3 (2 equiv), X-Phos (5% equiv), Pd(OAc)2 (4% 
equiv) in toluene (15 mL) at relux for 14 h to produce 180 mg of 8b in 76% yield, yellow 
solid, mp 86~88 ºC; 1H NMR δ ppm 2.11 (2H, t, J = 6.0 Hz, 3-CH2), 2.87 (2H, t, J = 6.0 Hz, 
PhCH2), 3.74 (2H, t, J = 6.0 Hz, NCH2), 3.73 (3H, s, OCH3), 6.13 (1H, d, J = 8.8 Hz, 
PhH-8), 6.53 (1H, dd, J = 8.8 and 2.8 Hz, PhH-7), 6.70 (1H, d, J = 2.8 Hz, PhH-5), 7.65 
(1H, dt, J = 8.0 and 2.0 Hz, ArH-7), 7.67 (1H, dt, J = 8.0 and 2.0 Hz, ArH-6), 7.95 (1H, dt, J 
= 8.0 and 2.0 Hz, ArH-5), 8.05 (1H, dd, J = 8.0 and 2.0 Hz, ArH-8), 8.41 (1H, s, ArH-3), 
9.15 (1H, s, ArH-1); MS m/z (%) 291 (M + H)+; HPLC purity 98.5%.
5.1.12. 6-Methoxy-3,4-dihydro-2H-1,4′-biquinoline (8c)—Prepared in the same 
manner as 8a. Starting with 4-chloroquinoline (7c, 150 mg, 0.92 mmol) and 3 (165 mg, 1.01 
mmol) in the presence of Cs2CO3 (2 equiv), X-Phos (0.05 equiv), Pd(OAc)2 (0.04 equiv) in 
toluene (15 mL) at reflux for 14 h to furnish 188 mg of 8c in 71% yield, yellow solid, mp 
41~43 ºC; 1H NMR δ ppm 2.11 (2H, t, J = 6.4 Hz, 3-CH2), 2.87 (2H, t, J = 6.4 Hz, PhCH2), 
3.74 (2H, t, J = 6.4 Hz, NCH2), 3.77 (3H, s, OCH3), 6.50 (1H, d, J = 8.8 Hz, PhH-8), 6.53 
(1H, dd, J = 8.8 and 2.4 Hz, PhH-7), 6.72 (1H, d, J = 2.4 Hz, PhH-5), 7.07 (1H, d, J = 8.0 
Hz, ArH-3), 7.44 (1H, t, J = 8.0 Hz, ArH-6), 7.68 (1H, t, J = 8.0 Hz, ArH-7), 7.95 (1H, d, J 
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= 8.0 Hz, ArH-5), 8.11 (1H, d, J = 8.0 Hz, ArH-8), 8.75 (1H, d, J = 8.0 Hz, ArH-2); MS m/z 
(%) 291 (M + H)+; HPLC purity 95.6% (mobile elution MeOH/water 70:30).
5.1.13. 6-Methoxy-3,4-dihydro-2H-1,8′-biquinoline (8d)—Prepared in the same 
manner as 8a. Starting with 8-chloroquinoline (7d, 550 mg, 3.37 mmol) and 3 (570 mg, 3.49 
mmol) in the presence of Cs2CO3, X-Phos, and Pd(OAc)2 in toluene (15 mL) at reflux for 
12 h to provide 598 mg of 8d, 61% yield, yellow solid, mp 86~88 ºC; 1H NMR δ ppm 2.00 
(2H, t, J = 6.4 Hz, 3-CH2), 2.93 (2H, t, J = 6.4 Hz, PhCH2), 3.74 (3H, s, OCH3), 3.74 (2H, t, 
J = 6.4 Hz, NCH2), 6.49 (1H, d, J = 8.0 Hz, PhH-8), 6.50 (1H, d, J = 8.0 Hz, PhH-7), 6.65 
(1H, s, PhH-5), 7.39 (1H, t, J = 8.0 Hz, ArH-6), 7.41 (1H, t, J = 8.0 Hz, ArH-3), 7.45 (1H, d, 
J = 8.0 Hz, ArH-5), 7.56 (1H, d, J = 8.0 Hz, ArH-4), 8.15 (1H, d, J = 8.0 Hz, ArH-7), 8.75 
(1H, d, J = 8.0 Hz, ArH-2); MS m/z (%) 291 (M + H)+; HPLC purity 95.2%.
5.2. Antiproliferative activity assay
Target compounds were assayed by the SRB method for cytotoxic activity using a HTCL 
assay according to procedures described previously.25,27 The cell line panel included human 
lung carcinoma (A-549), epidermoid carcinoma of the nasopharynx (KB), P-glycoprotein 
overexpressing epidermoid carcinoma of the nasopharynx (KBvin), and prostate cancer 
(DU145). The cytotoxic effects of each compound were expressed as GI50 values, which 
represent the molar drug concentrations required to cause 50% tumor cell growth inhibition.
5.3. Tubulin assays
Tubulin assembly was measured by turbidimetry at 350 nm as described previously.28 Assay 
mixtures containing 1.0 mg/mL (10 μM) of tubulin and varying compound concentrations 
were pre-incubated for 15 min at 30 ºC without guanosine 5′-triphosphate (GTP). The 
samples were placed on ice, and 0.4 mM GTP was added. Reaction mixtures were 
transferred to 0 ºC cuvettes, and turbidity development was followed for 20 min at 30 ºC 
following a rapid temperature jump. Compound concentrations that inhibited an increase in 
turbidity by 50% relative to a control sample were determined.
Inhibition of the binding of [3H]colchicine to tubulin was measured as described 
previously.29 Incubation of 1.0 μM tubulin with 5.0 μM [3H]colchicine and 5.0 or 1.0 μM 
inhibitor took place for 10 min at 37 ºC, the time at which about 40 60% of maximum 
colchicine binding occurs in control samples.
5.4. Aqueous solubility studies
Solubility was measured at pH 7.4 by using an HPLC-UV method. A test compound was 
initially dissolved in DMSO at a concentration of 1.0 mg/mL. Ten microliters of this stock 
solution was slowly dropped into 990 μL of water at pH 7.4. The mixture was stirred at 
room temperature for 4 h, and then centrifuged at 3000 rpm for 10 min. The clear water 
phase was transferred to a vial for analysis by HPLC. For quantification, a model 1200 
HPLC–UV (Agilent) system was used with an Agilent Eclipse XDB-C18 column (150 mm 
× 4.6 mm, 5 μm), and the eluent was MeOH/H2O (80:20) with 0.04% acetamide. The flow 
rate was 0.8 mL/min, injection volume was 20 μL, and detection wavelength was 254 nm. 
Aqueous concentration was determined by comparison of the peak area of the saturated 
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solution with a standard curve plotted peak area versus known concentrations, which were 
prepared by solutions of test compound in ACN at 50, 12.5, 3.13, 0.78, and 0.20 μg/mL. 
Each sample was performed in triplicate.
5.5. Log P measurement
One to two milligrams of test compound were dissolved in 1.0–2.0 mL of n-octane to obtain 
a 1.0 mg/mL solution. Next, the same volume of water as n-octane was added to each vial. 
The mixture was stirred at rt for 24 h and left without stirring overnight. The aqueous and 
organic phases of each mixture were transferred to separate vials for HPLC analysis. The 
instrument and conditions were the same as those for water solubility determinations. The 
log P was calculated by the peak area ratio in n-octane and in water.
5.6. Molecular modeling studies
All molecular modeling studies were performed with Discovery Studio 3.0 (Accelrys). The 
crystal structure of tubulin in complex with DAMA-colchicine (PDB code: 1SA0) was 
downloaded from the RCSB Protein Data Bank (http://www.rcsb.org/pdb) for use in the 
modeling study. CDOCKER was used to evaluate and predict in silico binding free energy 
of the inhibitors and for automated docking. The protein protocol was prepared by several 
operations, including standardization of atom names, insertion of missing atoms in residues 
and removal of alternate conformations, insertion of missing loop regions based on SEQRES 
data, optimization of short and medium size loop regions with the Looper algorithm, 
minimization of remaining loop regions, calculation of pK, and protonation of the structure. 
The receptor model was typed with the CHARMM force field. A binding sphere with a 
radius of 9.0 Å was defined through the original ligand (DAMA-colchicine) as the binding 
site for the study. The docking protocol employed total ligand flexibility, and the final 
ligand conformations were determined by the simulated annealing molecular dynamics 
search method set to a variable number of trial runs. Docked ligand 4a or 1a was further 
refined using in situ ligand minimization with the Smart Minimizer algorithm by standard 
parameters. The ligand and its surrounding residues within the above-defined sphere were 
allowed to move freely during the minimization, whereas the outer atoms were frozen. The 
implicit solvent model of Generalized Born with Molecular Volume (GBMV) was also used 
to calculate the binding energies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix A. Supplementary data
Supplementary data associated with this this article can be found in the online version. 
These data include HPLC purity data of target compounds, representive 1H and 13C NMR 
spetra, and MOL files of the most important compounds described in this article.
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Colchicine and analogs, drug candidates of VDAs, and our leads
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Leads and optimization strategy
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Predicted modes for 4a (orange stick for carbon atoms) binding with tubulin (PDB 1SA0) 
and overlapping with 1a (pink stick for carbon atoms) and DAMA-colchicine (cyan for 
carbon atoms, the native ligand of 1SA0). Surrounding amino acid side chains are shown in 
gray stick format and labeled. Hydrogen bonds are shown by green dashed lines, and the 
distances between ligands and protein are less than 3 Å.
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(i) 2a, anhydrous EtOH/NaHCO3, reflux, 3 h; (ii) 2b, i-PrOH/cHCl, reflux, 1 h; (iii) 
alkylamine, in EtOH or DMF (for 4d), mw, 150 ºC, 15 min; (iv) NaOMe/MeOH (for 4e), 
reflux, 1 h.
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(i) i-PrOH/cHCl, reflux; (ii) Pd(OAc)2/X-phos (mole ratio 2 – 4%), Cs2CO3, in toluene 
reflux.
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Table 3
Inhibition of tubulin polymerization and colchicine binding to tubulin by selected compounds.
Compound
Inhibition of tubulin assembly a Inhibition of colchicine binding b
IC50 (μM) ± SD
% Inhibition ± SD
5 μM 1 μM
1ac 0.93 ± 0.04 99 ± 0.6 95 ± 0.7
1bc 0.92 ± 0.06 95 ± 0.2 76 ± 0.1
4a 0.85 ± 0.07 78 ± 1 49 ± 5
4b 1.3 ± 0.04 89 ± 0.1 56 ± 5
4f 1.3 ± 0.02 91 ± 1 69 ± 4
4c 5.7 ± 0.1 29 ± 1 NTd
8a 2.6 ± 0.2 37 ± 2 NT
8b 3.3 ± 0.01 39 ± 4 NT
8d >20 NT NT
CA-4e 1.2 ± 0.1 97 ± 0.4 84 ± 0.3
a
Extent of assembly of 10 μM tubulin measured after 20 min at 30 °C.
b
Tubulin: 1 μM, [3H]colchicine: 5 μM, inhibitor 5 μM or 1 μM. Incubation was performed for 10 min at 37 °C.
c




Reference compound, a drug candidate in phase II/III clinical trials.
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Table 4
Aqueous solubility and lipophilicity of selected compounds a
Compound Solubility (μg/mL) Log P
4a 75.6 ± 0.89 3.43 ± 0.01
4b 2.55 ± 0.27 4.13 ± 0.03
a
Measured at pH 7.4 and presented as mean from three separate experiments with standard deviation (±SD).
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